Ruta graveolens, Pelargonium graveolens AND Hibiscus cannabinus AS NATURAL INHIBITORS OF GROWTH OF Candida albicans
Keywords:Antifungal, candidiasis, fungal resistance, medicinal plants
Candidiasis is an infection caused by fungi of the genus Candida, Candida albicans being the species that most causes the disease in Brazil. The Fluconazole is the conventional medicine used as a treatment of these infections; however, it causes many adverse reactions in the patient and its continued use can induce the resistance of the pathogen. The medicinal plants can be very effective as an alternative treatment of diseases and have been used in folk medicine for years. In this study, it was evaluated the antifungal activity of extracts of Ruta graveolens, Pelargonium graveolens and Hibiscus cannabinus against the fungal development of Candida albicans, comparing the efficiency of these extracts to Fluconazole. The extracts were prepared in the concentration of 1g of the plant for each 5 mL of alcohol 70%. The data were obtained using the agar diffusion method. The minimum inhibitory concentration test (MIC) was performed, and showed that R. graveolens was able of inhibiting 100% of the pathogen when using 100 mg.ml-1 concentration. From the results obtained, it was possible to conclude that R. graveolens was the most effective extract when compared to Fluconazole, suggesting that this extract can be used as an alternative to conventional treatment to improve the efficiency of current treatments. The extracts of P. graveolens and H. cannabinus also presented antifungal activity but in smaller proportion than Fluconazole.
How to Cite
Copyright (c) 2021 UNINGÁ JOURNAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
I declare/we declare that the text submitted here is original, of my own authorship and does not infringe any type of third party rights. The content is my/our sole responsibility. Possible research involving animals and/or human beings is in accordance with Resolution 196/96 of the National Health Council and its complements. I declare that I am/we are in possession of the written consent of patients and that the research and its procedures were timely and adequately approved by the Ethics Committee of the institution of origin. We further declare that all institutional affiliations and all sources of financial support for the work are duly informed. I certify that there is no commercial or associative interest that represents a conflict of interest related to the submitted work. If there is commercial interest, in addition to the technical and academic ones, in the publication of the article, the information will be reported during the text.